![](https://pharmaphorum.com/sites/default/files/2024-07/Ojemda_pachaging.jpg)
Ipsen builds again, licensing Day One glioma drug
Ipsen has signed yet another portfolio-expanding deal – its fifth of the year so far – claiming rights outside the US to a drug for common brain cancer glioma from Day One Biopharmaceuticals. The French pharma group is paying $111 million upfront for all …